Bio-Techne Corp
TECH65.700USD
+1.120+1.73%
Cierre 01/09, 16:00（ET）Cotizaciones retrasadas 15 min
10.23BCap. mercado
131.56P/E TTM
Más Datos de Bio-Techne Corp Compañía
Bio-Techne Corporation develop, manufacture and sell life science reagents, instruments and services for the research, diagnostics and bioprocessing markets worldwide. The Company’s segments include Protein Sciences segment and Diagnostics and Spatial Biology segment. The Protein Sciences segment is a developer and manufacturer of biological reagents used in all aspects of life science research, diagnostics and cell and gene therapy. The Diagnostics and Spatial Biology segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for the regulated diagnostics market, advanced tissue-based in-situ hybridization assays and instrumentation for spatial genomic and tissue biopsy analysis and genetic and oncology kits for research and clinical applications. Its product portfolio and application enable scientific investigations into biological processes and molecular diagnostics and progression of specific diseases.
Información de Bio-Techne Corp
Símbolo de cotizaciónTECH
Nombre de la empresaBio-Techne Corp
Fecha de salida a bolsaFeb 09, 1989
Director ejecutivoKelderman (Kim)
Número de empleados3100
Tipo de seguridadOrdinary Share
Fin del año fiscalFeb 09
Dirección614 Mckinley Pl N E
CiudadMINNEAPOLIS
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal55413
Teléfono16123798854
Sitio Webhttps://www.bio-techne.com/
Símbolo de cotizaciónTECH
Fecha de salida a bolsaFeb 09, 1989
Director ejecutivoKelderman (Kim)
Ejecutivos de Bio-Techne Corp
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. John L. Higgins
Mr. John L. Higgins
Independent Director
Independent Director
66.88K
+1640.00%
Mr. Kim Kelderman
Mr. Kim Kelderman
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
48.66K
-2303.00%
Mr. Robert V. (Bob) Baumgartner, CPA
Mr. Robert V. (Bob) Baumgartner, CPA
Independent Chairman of the Board
Independent Chairman of the Board
46.50K
+1640.00%
Dr. Joseph D. (Joe) Keegan, Ph.D.
Dr. Joseph D. (Joe) Keegan, Ph.D.
Independent Director
Independent Director
15.41K
+1640.00%
Dr. Rupert J. Vessey, Ph.D.
Dr. Rupert J. Vessey, Ph.D.
Independent Director
Independent Director
10.99K
+1640.00%
Ms. Julie L. Bushman
Ms. Julie L. Bushman
Independent Director
Independent Director
8.78K
+1640.00%
Mr. Shane Bohnen
Mr. Shane Bohnen
Senior Vice President, General Counsel, Corporate Secretary
Senior Vice President, General Counsel, Corporate Secretary
4.38K
--
Dr. Judith V. Klimovsky, M.D.
Dr. Judith V. Klimovsky, M.D.
Independent Director
Independent Director
3.78K
+1640.00%
Mr. James T. (Jim) Hippel
Mr. James T. (Jim) Hippel
Chief Financial Officer, Executive Vice President - Finance
Chief Financial Officer, Executive Vice President - Finance
--
--
Mr. David Clair
Mr. David Clair
Investor Relations
Investor Relations
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. John L. Higgins
Mr. John L. Higgins
Independent Director
Independent Director
66.88K
+1640.00%
Mr. Kim Kelderman
Mr. Kim Kelderman
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
48.66K
-2303.00%
Mr. Robert V. (Bob) Baumgartner, CPA
Mr. Robert V. (Bob) Baumgartner, CPA
Independent Chairman of the Board
Independent Chairman of the Board
46.50K
+1640.00%
Dr. Joseph D. (Joe) Keegan, Ph.D.
Dr. Joseph D. (Joe) Keegan, Ph.D.
Independent Director
Independent Director
15.41K
+1640.00%
Dr. Rupert J. Vessey, Ph.D.
Dr. Rupert J. Vessey, Ph.D.
Independent Director
Independent Director
10.99K
+1640.00%
Ms. Julie L. Bushman
Ms. Julie L. Bushman
Independent Director
Independent Director
8.78K
+1640.00%
Desglose de ingresos
Divisa: USDActualizado: mar., 6 de ene
Divisa: USDActualizado: mar., 6 de ene
FY2026Q1
FY2025
FY2025Q4
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2021
FY2020
FY2019
Por negocioUSD
Nombre
Ganancia
Proporción
Consumables
231.60M
80.82%
Service
27.48M
9.59%
Instruments
21.83M
7.62%
Royalty
5.65M
1.97%
Por regiónUSD
Nombre
Ganancia
Proporción
United States
155.24M
54.17%
EMEA, excluding U.K
65.13M
22.73%
Greater China
24.79M
8.65%
APAC, excluding Greater China
19.15M
6.68%
United Kingdom
13.21M
4.61%
Rest of World
9.05M
3.16%
Por negocio
Por región
Por negocioUSD
Nombre
Ganancia
Proporción
Consumables
231.60M
80.82%
Service
27.48M
9.59%
Instruments
21.83M
7.62%
Royalty
5.65M
1.97%
Estadísticas de accionistas
Actualizado: dom., 16 de nov
Actualizado: dom., 16 de nov
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
The Vanguard Group, Inc.
11.48%
BlackRock Institutional Trust Company, N.A.
5.64%
State Street Investment Management (US)
3.69%
Wellington Management Company, LLP
3.28%
Atlanta Capital Management Company, L.L.C.
3.17%
Otro
72.73%
Accionistas
Accionistas
Proporción
The Vanguard Group, Inc.
11.48%
BlackRock Institutional Trust Company, N.A.
5.64%
State Street Investment Management (US)
3.69%
Wellington Management Company, LLP
3.28%
Atlanta Capital Management Company, L.L.C.
3.17%
Otro
72.73%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor
58.57%
Investment Advisor/Hedge Fund
34.00%
Hedge Fund
8.06%
Bank and Trust
2.18%
Research Firm
1.96%
Pension Fund
1.35%
Sovereign Wealth Fund
1.24%
Individual Investor
0.28%
Insurance Company
0.24%
Participación institucional
Actualizado: jue., 1 de ene
Actualizado: jue., 1 de ene
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q4
1201
167.79M
107.68%
+389.22K
2025Q3
1198
161.18M
103.53%
-7.34M
2025Q2
1209
165.25M
105.41%
-730.33K
2025Q1
1245
168.10M
107.22%
+1.54M
2024Q4
1233
162.21M
102.61%
-6.39M
2024Q3
1205
159.40M
100.49%
-10.21M
2024Q2
1207
160.52M
101.86%
-12.24M
2024Q1
1216
162.56M
103.40%
-7.57M
2023Q4
1229
159.70M
100.98%
-3.97M
2023Q3
1217
156.41M
98.84%
-7.93M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
The Vanguard Group, Inc.
17.89M
11.48%
-504.17K
-2.74%
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
8.79M
5.64%
-7.47K
-0.08%
Sep 30, 2025
State Street Investment Management (US)
5.75M
3.69%
-105.19K
-1.80%
Sep 30, 2025
Wellington Management Company, LLP
5.12M
3.28%
+3.98M
+349.84%
Sep 30, 2025
Atlanta Capital Management Company, L.L.C.
4.94M
3.17%
+646.77K
+15.06%
Sep 30, 2025
Geode Capital Management, L.L.C.
4.93M
3.16%
+864.67K
+21.28%
Sep 30, 2025
Invesco Capital Management LLC
3.51M
2.26%
+275.06K
+8.49%
Sep 30, 2025
Neuberger Berman, LLC
3.31M
2.12%
+807.15K
+32.29%
Sep 30, 2025
T. Rowe Price Associates, Inc.
3.12M
2%
-5.50M
-63.78%
Sep 30, 2025
Maverick Capital, Ltd.
3.01M
1.93%
+3.01M
--
Sep 30, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 6 de dic
Actualizado: sáb., 6 de dic
Nombre
Proporción
Global X Genomics & Biotechnology ETF
4.29%
Invesco Biotechnology & Genome ETF
2.92%
Invesco S&P 500 Equal Weight Health Care ETF
2%
Neuberger Berman Small-Mid Cap ETF
1.78%
VanEck Biotech ETF
1.73%
Hilton Small-MidCap Opportunity ETF
1.7%
iShares Health Innovation Active ETF
1.68%
American Century Mid Cap Growth Impact ETF
1.47%
Thrivent Small-Mid Cap ESG ETF
1.34%
Invesco S&P 500 High Beta ETF
1.06%
Ver más
Global X Genomics & Biotechnology ETF
Proporción4.29%
Invesco Biotechnology & Genome ETF
Proporción2.92%
Invesco S&P 500 Equal Weight Health Care ETF
Proporción2%
Neuberger Berman Small-Mid Cap ETF
Proporción1.78%
VanEck Biotech ETF
Proporción1.73%
Hilton Small-MidCap Opportunity ETF
Proporción1.7%
iShares Health Innovation Active ETF
Proporción1.68%
American Century Mid Cap Growth Impact ETF
Proporción1.47%
Thrivent Small-Mid Cap ESG ETF
Proporción1.34%
Invesco S&P 500 High Beta ETF
Proporción1.06%
Dividendos
Un total de
250.90M
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Nov 05, 2025
TECH.NB Interim Cash Dividend of gross USD 0.08 paid on Nov 28, 2025 going ex on Nov 17, 2025
Nov 17, 2025
Nov 28, 2025
Nov 17, 2025
Aug 06, 2025
TECH.NB Interim Cash Dividend of gross USD 0.08 paid on Aug 29, 2025 going ex on Aug 18, 2025
Aug 18, 2025
Aug 29, 2025
Aug 18, 2025
May 07, 2025
TECH.NB Interim Cash Dividend of gross USD 0.08 paid on May 30, 2025 going ex on May 19, 2025
May 19, 2025
May 30, 2025
May 19, 2025
Feb 05, 2025
TECH.NB Final Cash Dividend of gross USD 0.08 paid on Feb 28, 2025 going ex on Feb 14, 2025
Feb 17, 2025
Feb 28, 2025
Feb 14, 2025
Oct 30, 2024
TECH.NB Interim Cash Dividend of gross USD 0.08 paid on Nov 22, 2024 going ex on Nov 08, 2024
Nov 11, 2024
Nov 22, 2024
Nov 08, 2024
Aug 07, 2024
TECH.NB Interim Cash Dividend of gross USD 0.08 paid on Aug 30, 2024 going ex on Aug 19, 2024
Aug 19, 2024
Aug 30, 2024
Aug 19, 2024
May 01, 2024
TECH.NB Interim Cash Dividend of gross USD 0.08 paid on May 24, 2024 going ex on May 10, 2024
May 13, 2024
May 24, 2024
May 10, 2024
Feb 01, 2024
TECH.NB Final Cash Dividend of gross USD 0.08 paid on Feb 26, 2024 going ex on Feb 09, 2024
Feb 12, 2024
Feb 26, 2024
Feb 09, 2024
Oct 31, 2023
TECH.NB Interim Cash Dividend of gross USD 0.08 paid on Nov 24, 2023 going ex on Nov 09, 2023
Nov 10, 2023
Nov 24, 2023
Nov 09, 2023
Aug 08, 2023
TECH.NB Interim Cash Dividend of gross USD 0.08 paid on Sep 01, 2023 going ex on Aug 17, 2023
Aug 18, 2023
Sep 01, 2023
Aug 17, 2023
Ver más
División de acciones
Fecha
Tipo
Relación
Nov 01, 2022
Split
1→4
Fecha
Tipo
Relación
Nov 01, 2022
Split
1→4
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Bio-Techne Corp?
Los cinco principales accionistas de Bio-Techne Corp son:
The Vanguard Group, Inc. posee 17.89M acciones, lo que representa el 11.48% del total de acciones.
BlackRock Institutional Trust Company, N.A. posee 8.79M acciones, lo que representa el 5.64% del total de acciones.
State Street Investment Management (US) posee 5.75M acciones, lo que representa el 3.69% del total de acciones.
Wellington Management Company, LLP posee 5.12M acciones, lo que representa el 3.28% del total de acciones.
Atlanta Capital Management Company, L.L.C. posee 4.94M acciones, lo que representa el 3.17% del total de acciones.
The Vanguard Group, Inc. posee 17.89M acciones, lo que representa el 11.48% del total de acciones.
BlackRock Institutional Trust Company, N.A. posee 8.79M acciones, lo que representa el 5.64% del total de acciones.
State Street Investment Management (US) posee 5.75M acciones, lo que representa el 3.69% del total de acciones.
Wellington Management Company, LLP posee 5.12M acciones, lo que representa el 3.28% del total de acciones.
Atlanta Capital Management Company, L.L.C. posee 4.94M acciones, lo que representa el 3.17% del total de acciones.
¿Cuáles son los tres principales tipos de accionista de Bio-Techne Corp?
Los tres principales tipos de accionista de Bio-Techne Corp son:
The Vanguard Group, Inc.
BlackRock Institutional Trust Company, N.A.
State Street Investment Management (US)
The Vanguard Group, Inc.
BlackRock Institutional Trust Company, N.A.
State Street Investment Management (US)
¿Cuántas instituciones poseen acciones de Bio-Techne Corp (TECH)?
A fecha de 2025Q4, 1201 instituciones poseen acciones de Bio-Techne Corp, con un valor de mercado combinado de aproximadamente 167.79M, lo que representa el 107.68% del total de acciones. En comparación con el 2025Q3, el accionariado institucional ha aumentado en 4.16%.
¿Cuál es la mayor fuente de ganancias de Bio-Techne Corp?
El FY2026Q1, el segmento empresarial Consumables generó la ganancia más alta para Bio-Techne Corp, ascendiendo a 231.60M y representando el 80.82% de la ganancia total.
